Research detail
05.12 2012 11:46:12
go backVeropharm reports weak results
by Anton Safonov
Veropharm has published operating and financial results for January-September, 2012, based on IFRS. The results are viewed as negative. Despite EBITDA margin expansion, revenue declined, as did net profit.
This research is available only to subscribers.
Please
login
to continue
To subscribe please contact us on sales@investcafe.co.uk or +7 495 792-06-19
Free Samples
- Tatneft – stability is second nature (by Grigory Birg)
- Gazprom: not so humble giant promises great returns (by Grigory Birg)
- Rosneft – Near Perfect (by Grigory Birg)
- NOVATEK — clear opportunities ahead (by Grigory Birg)
- Transneft: struggling to see clear potential due to IPO uncertainty (by Grigory Birg)
